Logo Informatori.Info
Rassegna Stampa

Rassegna Stampa per il settore farmaceutico

In questa pagina potrete trovare articoli relativi al settore farmceutico, come ad esempio informazioni su farmaci, sindacati di categoria, aziende farmaceutiche e molto altro.

Categoria

lug22International Guidelines Say Use Treat-to-Target for SpA, PsA
  Updated guidelines for axial spondyloarthritis (SpA) and peripheral spondyloarthritis (PsA) include stronger support for treating to the target of remission, but one expert worries they may result in overtreatment. An international task force published the recommendations online Ju...


lug20EU approves LEO Pharma’s psoriasis biologic
A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy. LEO Pharma’s Kyntheum (brodalumab) is a novel biologic and ...


lug17Safety scare prompts FDA to reject Amgen’s romosozumab
The FDA has rejected Amgen’s application for approval of osteoporosis candidate romosozumab. Officials knocked back the filing after phase 3 data linked the sclerostin-targeting antibody to an increased risk of cardiovascular adverse events. Amgen said it no longer expected to win FDA approva...


lug17Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Novartis could take the top spot from Pfizer in prescription-drug sales by 2022. So what? Pfizer (NYSE:PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up Nov...


lug16Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
ZURICH, July 14 (Reuters) - Switzerland's Novartis is stocking up cheaper versions of the world's top-selling arthritis medicines, hoping a broad portfolio gives it an edge on rivals with narrower offerings. * Novartis hawks cut-rate arthritis drug copies * Hopes broad offering gives it bo...


lug15FDA clears Philips' light therapy wearable for mild psoriasis
Philips scored FDA clearance for its wearable light therapy device for the treatment of psoriasis. The rechargeable device delivers blue LED light to the skin in a drug-free approach that controls the symptoms of mild psoriasis. Characterized by patches of thick, red inflamed skin covered wit...


lug15J&J's Tremfya approved, further crowding IL-inhibitor market
The Food and Drug Administration on Thursday approved Johnson & Johnson's latest psoriasis treatment, bringing another player into the increasingly crowded market of interleukin (IL) inhibiting drugs. Tremfya (guselkumab) received the green light for adults with moderate to severe plaque psor...


apr22CHMP Recommends Skilarence for Psoriasis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended granting marketing authorization for dimethyl fumarate (DMF; Skilarence , Almirall, SA) for the treatment of psoriasis. "Thanks to its efficacy and safety profile, this new oral...


mar19Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis
Novartis has been mining a pivotal study of Entresto, its heart-failure med, for more insights ever since it was first published in 2014. Now, a new analysis shows that Entresto beat an older med at reducing blood sugar levels in heart failure patients with diabetes. By breaking out and analy...


feb17Would Pfizer, Roche or Novartis megamerge with BMS? Rumors say they're crunching numbers now
Last month, a couple of analysts addressed Bristol-Myers Squibb as a takeover target for some rival pharma giant. The gist? The combination of disappointments on its cancer blockbuster Opdivo plus a solid product line-up could well put a bullseye on the company—and its “very logical, very rational”...


feb17Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Pfizer Inc. PFE, +0.33% said early Thursday that its Xeljanz drug met its primary endpoint in combination with methotrexate as compared to AbbVie's ABBV, -0.28% blockbuster drug Humira, although it didn't meet the primary endpoint on its own. The results of the phase 3B/4 trial, which...


feb16FDA Approves brodalumab (Siliq) for Psoriasis
The US Food and Drug Administration (FDA) today approved an injectable biologic called brodalumab ( Siliq , Valeant Pharmaceuticals) to treat adults with moderate-to-severe psoriasis, but the approval comes with important yellow flags. The agency ordered a boxed label warning on an obser...


nov28Janssen brings psoriasis therapy guselkumab to the EMA
Janssen has filed its potential new psoriasis therapy guselkumab with the European Medicines Agency, hot on the heels of the drug's submission in the US. Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which is known to play a key role in the devel...


nov22Biosimilari, l’Aifa mette in stand by i criteri sull’equivalenza terapeutica
L'Agenzia Italiana del Farmaco comunica la sospensione dell'efficacia della Determinazione Aifa-Dg n. 458 del 31 marzo 2016, concernente “Riforma della Determinazione recante procedura di applicazione dell'articolo 15, comma 11 ter, del decreto legge 6 luglio 2012, n. 95 (disposizioni urgenti per l...


nov17European Studies of Infliximab Biosimilar Reassuring
The success of the infliximab biosimilar in two European studies could increase uptake of the agent in the United States, experts said here at the American College of Rheumatology 2016 Annual Meeting. No red flags were raised in the Norwegian and Danish studies when patients switched from the...


Cerca la Notizia
Argomenti
Skip Navigation Links.

AIFA

AIISF

Articoli Scientifici

ASL

Associazioni-Sindacati

Auto Aziendale

Aziende Farmaceutiche

British Medical Journal

Codice Strada

Congressi

Contravvenzioni

Dispositivi Medici

Enasarco

Eventi

Eventi ECM

Farmaci

Farmacie

Farmindustria

Faschim

Federaisf

Fonchim

Informatori

Jama

Lancet

New England

Parafarmacie

RSU Aziende

Sanita'

SLF Cobas